TWI827590B - 稠和雙環C5aR拮抗劑之前藥 - Google Patents

稠和雙環C5aR拮抗劑之前藥 Download PDF

Info

Publication number
TWI827590B
TWI827590B TW108111647A TW108111647A TWI827590B TW I827590 B TWI827590 B TW I827590B TW 108111647 A TW108111647 A TW 108111647A TW 108111647 A TW108111647 A TW 108111647A TW I827590 B TWI827590 B TW I827590B
Authority
TW
Taiwan
Prior art keywords
group
mmol
alkyl
diethylphenyl
compound
Prior art date
Application number
TW108111647A
Other languages
English (en)
Chinese (zh)
Other versions
TW202002966A (zh
Inventor
平臣 樊
敏瑜 雷
羅瑾德 斯穎
帆克 羅迪 馬利
曾一斌
朋烈 張
Original Assignee
美商卡默森屈有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商卡默森屈有限公司 filed Critical 美商卡默森屈有限公司
Publication of TW202002966A publication Critical patent/TW202002966A/zh
Application granted granted Critical
Publication of TWI827590B publication Critical patent/TWI827590B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW108111647A 2018-04-02 2019-04-02 稠和雙環C5aR拮抗劑之前藥 TWI827590B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862651512P 2018-04-02 2018-04-02
US62/651,512 2018-04-02

Publications (2)

Publication Number Publication Date
TW202002966A TW202002966A (zh) 2020-01-16
TWI827590B true TWI827590B (zh) 2024-01-01

Family

ID=68054774

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108111647A TWI827590B (zh) 2018-04-02 2019-04-02 稠和雙環C5aR拮抗劑之前藥

Country Status (17)

Country Link
US (2) US20190300526A1 (https=)
EP (1) EP3773563B1 (https=)
JP (1) JP7337833B2 (https=)
KR (1) KR102809631B1 (https=)
CN (1) CN111954525B (https=)
AR (1) AR114464A1 (https=)
AU (1) AU2019246969B2 (https=)
BR (1) BR112020019822A2 (https=)
CA (1) CA3095184A1 (https=)
ES (1) ES2993034T3 (https=)
IL (1) IL277608B2 (https=)
MA (1) MA52245A (https=)
MX (1) MX2020010390A (https=)
SG (1) SG11202009588PA (https=)
TW (1) TWI827590B (https=)
WO (1) WO2019195159A1 (https=)
ZA (1) ZA202006154B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
US10562896B2 (en) 2017-05-31 2020-02-18 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
JP2020532551A (ja) 2017-09-03 2020-11-12 アンジオン バイオメディカ コーポレーション Ｒｈｏ関連コイルドコイルキナーゼ（ＲＯＣＫ）阻害剤としてのビニルヘテロ環
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
WO2019126424A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
WO2020227337A1 (en) * 2019-05-07 2020-11-12 Bristol-Myers Squibb Company Prodrug compounds
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
KR20220118419A (ko) 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물
JP7679383B2 (ja) * 2019-12-19 2025-05-19 ジェンフィット ＲＯＲγモジュレーターのホスフェート誘導体及びその使用
HRP20241159T1 (hr) * 2020-02-07 2024-12-06 Gasherbrum Bio, Inc. Heterociklički agonisti za glp-1
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
US20220047592A1 (en) * 2020-08-13 2022-02-17 Chemocentryx, Inc. METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
CN116368140A (zh) 2020-09-10 2023-06-30 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2022063050A1 (zh) * 2020-09-28 2022-03-31 四川科伦博泰生物医药股份有限公司 吡唑类化合物及其制备方法和用途
WO2022140258A1 (en) * 2020-12-21 2022-06-30 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
CN114933584B (zh) * 2021-08-09 2022-12-27 上海贵之言医药科技有限公司 一种二氢-2h-异吲哚酯类化合物
MX2024004846A (es) 2021-10-22 2024-05-03 Jiangsu Hengrui Pharmaceuticals Co Ltd Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
CN113666985A (zh) * 2021-10-22 2021-11-19 山东谷雨春生物科技有限公司 一种曲安奈德的制备方法
CN116023321B (zh) * 2022-12-30 2024-11-29 中国药科大学 Sting抑制剂前药及其医药用途
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925846A (en) * 1986-06-04 1990-05-15 Roussel Uclaf 2-thiazolyl-imidazo[1,2,-a]pyrimidines
US6893659B2 (en) * 1997-03-28 2005-05-17 Sanoti-Synthelabo Pharmaceutical composition for oral administration of a N-piperidino-3- pyrazolecarboxamide derivative, its salts and their solvates
US20060205948A1 (en) * 2003-04-23 2006-09-14 Pfizer Inc Cannabinoid receptor ligands and uses thereof
TW201803850A (zh) * 2016-04-04 2018-02-01 卡默森屈有限公司 可溶性C5aR拮抗劑

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
DK1320531T3 (da) 2000-08-10 2011-01-03 Pfizer Italia Srl Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
JP5260818B2 (ja) 2000-09-29 2013-08-14 ノバルティス・インターナショナル・ファーマシューティカル・リミテッド 高親和性低分子Ｃ５ａ受容体調節物質
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
DE10231789A1 (de) 2001-07-19 2003-02-06 Luk Lamellen & Kupplungsbau Verfahren, Vorrichtung und deren Verwendung zum Betrieb eines Kraftfahrzeuges
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
CA2479930A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
CA2480082A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
WO2006042102A2 (en) 2004-10-05 2006-04-20 Neurogen Corporation Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
WO2007051062A2 (en) 2005-10-28 2007-05-03 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2009155565A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
BR112012004335A8 (pt) 2009-09-02 2016-06-21 Merck Sharp & Dohme Composto, composição farmacêutica, e, uso do composto.
RS56332B1 (sr) 2010-06-24 2017-12-29 Chemocentryx Inc Antagonisti c5ar
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
KR20150042271A (ko) 2012-08-16 2015-04-20 얀센 파마슈티카 엔.브이. N형 칼슘 채널 차단제로서의 치환된 피롤로피라졸
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US10562896B2 (en) * 2017-05-31 2020-02-18 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
WO2018222601A1 (en) * 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
WO2019126424A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925846A (en) * 1986-06-04 1990-05-15 Roussel Uclaf 2-thiazolyl-imidazo[1,2,-a]pyrimidines
US6893659B2 (en) * 1997-03-28 2005-05-17 Sanoti-Synthelabo Pharmaceutical composition for oral administration of a N-piperidino-3- pyrazolecarboxamide derivative, its salts and their solvates
US20060205948A1 (en) * 2003-04-23 2006-09-14 Pfizer Inc Cannabinoid receptor ligands and uses thereof
TW201803850A (zh) * 2016-04-04 2018-02-01 卡默森屈有限公司 可溶性C5aR拮抗劑

Also Published As

Publication number Publication date
MA52245A (fr) 2021-04-28
CA3095184A1 (en) 2019-10-10
SG11202009588PA (en) 2020-10-29
US20210052612A1 (en) 2021-02-25
US20190300526A1 (en) 2019-10-03
EP3773563C0 (en) 2024-10-16
EP3773563B1 (en) 2024-10-16
CN111954525B (zh) 2023-12-26
US11608336B2 (en) 2023-03-21
ES2993034T3 (en) 2024-12-20
ZA202006154B (en) 2025-04-30
JP2021519794A (ja) 2021-08-12
KR20200139751A (ko) 2020-12-14
AU2019246969B2 (en) 2024-10-24
WO2019195159A1 (en) 2019-10-10
IL277608B2 (en) 2023-09-01
TW202002966A (zh) 2020-01-16
IL277608A (en) 2020-11-30
KR102809631B1 (ko) 2025-05-16
NZ768284A (en) 2024-04-26
EP3773563A4 (en) 2021-12-29
MX2020010390A (es) 2021-01-15
IL277608B1 (en) 2023-05-01
AR114464A1 (es) 2020-09-09
AU2019246969A1 (en) 2020-10-15
JP7337833B2 (ja) 2023-09-04
RU2020135500A (ru) 2022-05-05
BR112020019822A2 (pt) 2021-03-16
CN111954525A (zh) 2020-11-17
EP3773563A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
TWI827590B (zh) 稠和雙環C5aR拮抗劑之前藥
JP7253557B2 (ja) Ｃ５ａＲ阻害剤としてのジアリール置換５，５－縮合環化合物
JP7254082B2 (ja) Ｃ５ａＲ阻害剤としてのジアリール置換６，５－縮合環化合物
RU2794327C2 (ru) ПРОЛЕКАРСТВА СОПРЯЖЕННО-БИЦИКЛИЧЕСКИХ АНТАГОНИСТОВ C5aR
RU2785549C2 (ru) ДИАРИЛ-ЗАМЕЩЕННЫЕ 5,5 СОПРЯЖЕННЫЕ ЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ C5aR
RU2796983C2 (ru) ДИАРИЛ-ЗАМЕЩЕННЫЕ 6,5-СОПРЯЖЕННЫЕ ЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ C5aR